세계의 기저세포암 치료 시장 보고서(2025년)
Basal Cell Carcinoma Treatment Global Market Report 2025
상품코드 : 1824595
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 기저세포암 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 9.6%로 확대되어 117억 3,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 삶의 질(QOL)에 대한 주목의 고조, 노화, 면역요법의 연구개발의 진전, 정부의 대처 등에 기인하고 있습니다. 예측 기간의 주요 동향으로는 치료 방법의 진보, 조기 발견 기술, 표적 치료의 진보, 원격 의료 통합 등이 있습니다.

향후 5년간의 예측 성장률 9.6%는 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국 간의 관세의 영향 때문입니다. 관세의 상승은 스위스나 영국에서 조달하는 모스 수술 기구와 헤지호그 경로 억제제의 가격을 밀어 올리고 피부암 치료비를 악화시켜 수술 옵션을 제한함으로써 미국의 피부과에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

피부암, 특히 기저세포암의 발생이 증가하고 있는 것이, 향후의 치료 시장의 성장을 가속할 것으로 예측됩니다. 피부암은 비정상적인 피부 세포의 통제 불가능한 증식을 특징으로 하며, 종종 태양과 태닝 장치에서 자외선(UV) 노출과 관련이 있습니다. 피부암, 특히 기저세포암의 유병률 증가는 표적을 좁힌 전문적인 치료 옵션의 필요성을 강조하고, 이 특정한 암 유형에 대처하기 위해 조정된 효과적인 약제의 개발과 이용 가능성을 촉진하고 있습니다. 예를 들어 2023년 1월 미국암협회(American Cancer Society, Inc.)는 미국에서는 매년 약 540만명의 기저세포암과 편평상피암 환자가 발생하여 약 330만명이 이환되어 기저세포암은 10례 중 8례를 차지한다고 보고하고 있습니다. 따라서 기저세포암을 포함한 피부암의 이환율 증가는 치료시장의 성장을 자극하게 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Basal cell carcinoma (BCC) is a form of skin cancer originating from basal cells, which are responsible for generating new skin cells. It often appears as a small, translucent lump but can have varied presentations. Effective treatment strategies for basal cell carcinoma (BCC) involve tumor removal, considering tumor characteristics, location, size, patient preferences and the practicality of follow-up appointments.

The main types of basal cell carcinoma treatment are surgery, medication and other treatments. Surgery refers to a branch of medicine that involves treating diseases and conditions through operative or manual procedures, including cutting, abrading, suturing, or otherwise physically changing body tissues and organs and surgeries are also vital for basal cell carcinoma patients, removing tumors to achieve effective treatment and minimize damage. The treatments options are administered by oral, parenteral and other routes and are distributed through hospital pharmacy, online pharmacy and retail pharmacy channels for end users such as hospitals, specialty clinics and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The basal cell carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides basal cell carcinoma treatment market statistics, including basal cell carcinoma treatment industry global market size, regional shares, competitors with a basal cell carcinoma treatment market share, detailed basal cell carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the basal cell carcinoma treatment industry. This basal cell carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The basal cell carcinoma treatment market size has grown strongly in recent years. It will grow from $7.42 billion in 2024 to $8.13 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increasing prevalence of skin cancer, demand for laser therapy, demand for effective and minimally invasive treatments, rising awareness of basal cell carcinoma treatment.

The basal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $11.73 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing focus on quality of life, aging population, growing research and development in immunotherapies, government initiatives. Major trends in the forecast period include advancements in treatment modalities, early detection technologies, advancements in targeted therapies, telemedicine integration.

The forecast of 9.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. dermatology by driving up the cost of Mohs surgery instruments and hedgehog pathway inhibitors sourced from Switzerland and the UK, exacerbating skin cancer treatment expenses and limiting surgical options. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing occurrences of skin cancer, notably basal cell carcinoma, are anticipated to drive growth in the treatment market in the future. Skin cancer is characterized by the uncontrolled growth of abnormal cells in the skin, often linked to exposure to ultraviolet (UV) radiation from the sun or tanning devices. The growing prevalence of skin cancer, particularly basal cell carcinoma, underscores the need for targeted and specialized treatment options, driving the development and availability of effective medications tailored to combat this specific cancer type. For example, in January 2023, the American Cancer Society, Inc., reported that the United States witnessed approximately 5.4 million cases of basal and squamous cell skin cancer each year, affecting around 3.3 million individuals, with basal cell carcinoma accounting for eight out of every ten cases. Consequently, the increasing incidence of skin cancer, including basal cell carcinoma, is poised to stimulate growth in the treatment market.

The global increase in the elderly population is anticipated to act as a driving force behind the growth of the basal cell carcinoma treatment market. The term 'geriatric population' pertains to individuals typically aged 65 and older, and this group is more vulnerable to basal cell carcinoma (BCC) due to prolonged sun exposure, a primary risk factor for BCC. Consequently, the aging population's heightened susceptibility contributes to a greater demand for the diagnosis and treatment of BCC. For instance, data from the United Nations Department of Economic and Social Affairs in July 2022 predicts that the percentage of the global population aged 65 and above is set to rise from 10% in 2022 to 16% by 2050. Hence, the increasing geriatric population worldwide is a key driver for the growth of the basal cell carcinoma treatment market.

Key companies in the basal cell carcinoma treatment market are focusing on advancing technologies such as lyophilization (freeze-drying) to improve the efficacy and shelf-life of topical treatments, as well as to enhance the precise delivery of active ingredients to targeted cancer cells. Lyophilization is a process where a substance is frozen and then placed under a vacuum, causing the water to sublimate and leaving the material in a stable, dry form. For example, in August 2022, Accord Healthcare, Inc., a US-based pharmaceutical company, introduced Carmustine, a generic chemotherapy drug approved by the FDA for treating certain brain tumors and blood cancers. Carmustine is used for treating various malignant brain tumors, including glioblastomas, astrocytomas, and medulloblastomas, as well as relapsed or refractory Hodgkin's lymphoma and multiple myelomas, among other blood cancers.

In July 2022, Regeneron Pharmaceuticals Inc., a US-based biopharmaceutical company, secured exclusive licensing rights to Libtayo from Sanofi SA for a sum of $900 million. This acquisition strengthens Regeneron Pharmaceuticals, Inc.'s presence in the field of oncology by granting it the rights to develop, market, and manufacture Libtayo, a prescription medication designed for the treatment of individuals with cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, two types of skin cancer. Sanofi SA, a pharmaceutical firm headquartered in France, is responsible for the development of the basal cell carcinoma treatment drug, Libtayo.

Major companies operating in the basal cell carcinoma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Fresenius Kabi AG, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Incyte Corporation, Ono Pharma UK Ltd., Cipla Inc., Lupin Limited, Mallinckrodt Pharmaceuticals, LEO Pharma A/S, BeiGene Ltd., Taro Pharmaceutical Industries Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Genentech USA Inc., Palvella Therapeutics LLC.

North America was the largest region in the basal cell carcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in basal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the basal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The basal cell carcinoma treatment market consists of revenues earned by entities by providing surgical excision, Moh's surgery, cryosurgery, photodynamic therapy (PDT) and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The basal cell carcinoma treatment market also includes sales of topical treatment and advanced medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Basal Cell Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on basal cell carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for basal cell carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The basal cell carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Basal Cell Carcinoma Treatment Market Characteristics

3. Basal Cell Carcinoma Treatment Market Trends And Strategies

4. Basal Cell Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Basal Cell Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Basal Cell Carcinoma Treatment Market Segmentation

7. Basal Cell Carcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Basal Cell Carcinoma Treatment Market

9. China Basal Cell Carcinoma Treatment Market

10. India Basal Cell Carcinoma Treatment Market

11. Japan Basal Cell Carcinoma Treatment Market

12. Australia Basal Cell Carcinoma Treatment Market

13. Indonesia Basal Cell Carcinoma Treatment Market

14. South Korea Basal Cell Carcinoma Treatment Market

15. Western Europe Basal Cell Carcinoma Treatment Market

16. UK Basal Cell Carcinoma Treatment Market

17. Germany Basal Cell Carcinoma Treatment Market

18. France Basal Cell Carcinoma Treatment Market

19. Italy Basal Cell Carcinoma Treatment Market

20. Spain Basal Cell Carcinoma Treatment Market

21. Eastern Europe Basal Cell Carcinoma Treatment Market

22. Russia Basal Cell Carcinoma Treatment Market

23. North America Basal Cell Carcinoma Treatment Market

24. USA Basal Cell Carcinoma Treatment Market

25. Canada Basal Cell Carcinoma Treatment Market

26. South America Basal Cell Carcinoma Treatment Market

27. Brazil Basal Cell Carcinoma Treatment Market

28. Middle East Basal Cell Carcinoma Treatment Market

29. Africa Basal Cell Carcinoma Treatment Market

30. Basal Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles

31. Basal Cell Carcinoma Treatment Market Other Major And Innovative Companies

32. Global Basal Cell Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Basal Cell Carcinoma Treatment Market

34. Recent Developments In The Basal Cell Carcinoma Treatment Market

35. Basal Cell Carcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기